Conclusions from today's poster | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website

CORT   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3171 of 3186  at  6/22/2020 6:03:19 PM  by


Conclusions from today's poster

 CONCLUSIONS ƒ Glucocorticoid excess affects significantly more genes in ACC than other hormones. ƒ In GC+ ACC, expression of steroid synthesis genes was elevated while immune-related genes were suppressed. o Normal adrenal cells express steroid synthesis genes but not immune-related genes. o Steroid synthesis genes were hypomethylated in GC+ cases, while no difference in methylation between GC+ and GC- cases was found for immune genes. o Furthermore, fewer infiltrating immune cells (T cells and NKT cells) were found in GC+ cases compared to GC-, suggesting that immune effects are due to changes in immune cell infiltrate rather than transcriptional changes. ƒ Tumor mutation burden was higher in GC+ ACC cases, which may be caused by the observed immune suppression or immune cell exclusion that may, in turn, be related to higher tolerance of non-self-antigens in GC+ cases. ƒ A published GR activity score showed no difference between GC+ and GC- cases, which may be due to locally high concentrations of GC in the adrenal gland regardless of systemic GC levels. o In contrast, immune infiltration into ACC tumors may be negatively affected by the exposure of lymph nodes to elevated GC activity. ƒ A newly derived gene signature predicts the highest frequency of GC+-like tumors in uveal and skin cutaneous melanomas. ƒ The observed reduced abundance of immune cells and immune-related transcripts in GC+ ACC provides insight into the mechanisms by which GC may limit response to ICI therapy. o GR antagonism may increase immune related transcripts or immune cell infiltration, thus promoting tumor immune response in GC+ ACC and other malignancies with elevated GC activity. o This hypothesis will be tested in a phase 1 oncology trial of relacorilant combined with ICI (CORT125134-551, NCT04373265).

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 134
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by